Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ron Bose

Showing results (11-20 of 78) with videos related to

Pageof 8
Sort By:
Molecular & Cellular Proteomics : MCP|October 30, 2012
Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancersAlaina P Boyer, Timothy S Collier, Ilan Vidavsky, et al.
Plos One|July 5, 2013
Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing DataRunjun D Kumar, Li-Wei Chang, Matthew J Ellis, et al.
BMC Nephrology|November 10, 2024
Sacituzumab-govitecan-induced severe acute tubulointerstitial nephritis requiring hemodialysisGeneva Guarin, Audrey Netzel, Karen Marie Flores, et al.
Current Opinion in Structural Biology|November 7, 2006
Protein tyrosine kinase-substrate interactionsRon Bose, Marc A Holbert, Kerry A Pickin, et al.
The Journal of Biological Chemistry|July 12, 2013
Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interfaceTimothy S Collier, Karthikeyan Diraviyam, John Monsey, et al.
Nature|November 30, 2007
Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interfaceXuewu Zhang, Kerry A Pickin, Ron Bose, et al.
The Journal of Biological Chemistry|November 23, 2016
Biophysical Evidence for Intrinsic Disorder in the C-terminal Tails of the Epidermal Growth Factor Receptor (EGFR) and HER3 Receptor Tyrosine KinasesTheodore R Keppel, Kwabena Sarpong, Elisa M Murray, et al.
Bioinformatics (Oxford, England)|July 26, 2015
Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing dataRunjun D Kumar, Adam C Searleman, S Joshua Swamidass, et al.
Molecular & Cellular Proteomics : MCP|March 23, 2011
Carboxyl-group footprinting maps the dimerization interface and phosphorylation-induced conformational changes of a membrane-associated tyrosine kinaseHao Zhang, Wei Shen, Don Rempel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 12, 2015
HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase InhibitorNoa Efrat Ben-Baruch, Ron Bose, Shyam M Kavuri, et al.
Pageof 8

Showing results (11-20 of 78) with videos related to

Sort By:
Pageof 8
Molecular & Cellular Proteomics : MCP|October 30, 2012
Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancersAlaina P Boyer, Timothy S Collier, Ilan Vidavsky, et al.
Plos One|July 5, 2013
Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing DataRunjun D Kumar, Li-Wei Chang, Matthew J Ellis, et al.
BMC Nephrology|November 10, 2024
Sacituzumab-govitecan-induced severe acute tubulointerstitial nephritis requiring hemodialysisGeneva Guarin, Audrey Netzel, Karen Marie Flores, et al.
Current Opinion in Structural Biology|November 7, 2006
Protein tyrosine kinase-substrate interactionsRon Bose, Marc A Holbert, Kerry A Pickin, et al.
The Journal of Biological Chemistry|July 12, 2013
Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interfaceTimothy S Collier, Karthikeyan Diraviyam, John Monsey, et al.
Nature|November 30, 2007
Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interfaceXuewu Zhang, Kerry A Pickin, Ron Bose, et al.
The Journal of Biological Chemistry|November 23, 2016
Biophysical Evidence for Intrinsic Disorder in the C-terminal Tails of the Epidermal Growth Factor Receptor (EGFR) and HER3 Receptor Tyrosine KinasesTheodore R Keppel, Kwabena Sarpong, Elisa M Murray, et al.
Bioinformatics (Oxford, England)|July 26, 2015
Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing dataRunjun D Kumar, Adam C Searleman, S Joshua Swamidass, et al.
Molecular & Cellular Proteomics : MCP|March 23, 2011
Carboxyl-group footprinting maps the dimerization interface and phosphorylation-induced conformational changes of a membrane-associated tyrosine kinaseHao Zhang, Wei Shen, Don Rempel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 12, 2015
HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase InhibitorNoa Efrat Ben-Baruch, Ron Bose, Shyam M Kavuri, et al.
Pageof 8